Q1 2022 Results
Company overview
Financial performance
Financial review
2022 priorities
Innovation: Pipeline overview
and strength and depth in oncology
Appendix
Innovation: Clinical trials
References
Abbreviations
Selected assets, nearly all with exclusivity into 2030+
Solid Tumors
New for Q1
Hematology
Asset
Indication
Peak Sales
Next Milestone/ Status
Submission
Asset
Indication
Peak Sales
Next Milestone/ Status
Submission
Kisqali®
HR+/HER2- BC (adj)
Ph3 NATALEE readout event- 2023
driven, expected 2023
Canakinumab
NSCLC adjuvant
Ph3 CANOPY-A readout
in 2022
2023
ScemblixⓇ
(asciminib)
Iptacopan²
CML 3L
CML 1L
PNH
US and JP approved
Ph3 ongoing
2025
Readout in 2022 (APPLY-PNH -
2023
enrollment completed)
PluvictoⓇ
mCRPC post-taxane
US approved
aHUS
Ph3 ongoing
2025
mCRPC pre-taxane
Ph3 PSMAfore readout
event-driven, end 20221
2023
Sabatolimab
HR-MDS
Ph2 STIMULUS-MDS-1
2022/2023
continues to PFS readout³
MHSPC
Ph3 PSMAddition ongoing
2024
JDQ443
2/3L NSCLC (mono)
Tislelizumab²
KRAS inhibitor
TNO155
SHP2 inhibitor
NSCLC (combo)
Solid tumors: multiple combinations being explored in ongoing trials
2L esophageal cancer
NSCLC
Ph3 start in H2 2022
Ph2 ongoing
2024
AML
2026+
YTB323
CD19 CAR-T
Non-Hodgkin's
Lymphoma
Ph3 STIMULUS-MDS-2 ongoing
Ph2 STIMULUS-AML-1 ongoing
Ph3 start 2022
2024
2025
Submitted in EU
PHE885
BCMA CART-T
Submitted in EU
H2 2022 2L US submission
Multiple
myeloma
Unprobabilized peak sales (USD): ⚫ <1bn
Ph2 initiated
2024
.. 1-2bn
... >2bn
Other indications
Ociperlimab²
NSCLC
TIGIT mab
Other indications
Ongoing trials
Ph3 ongoing4
Ongoing trials4; additional
Ph3 study initiation H2 2022
'Wild Cards' |
1. Could move to early 2023.
NIS793 (1L MPDAC: Ph3 ongoing, 1L metastatic colorectal cancer: Ph2 ongoing)
2. Peak sales potential based on all studied indications; Novartis territories. 3. Planned DMC readout for CR completed, study continues blinded to PFS readout, with submission in 2022/2023 using PFS and/or
OS outcomes of Ph2 and/or Ph3 trial. 4. Active trials are being conducted by BeiGene, option deal.
34 Investor Relations | Q1 2022 Results
U NOVARTIS | Reimagining MedicineView entire presentation